What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence for clinical effectiveness is primarily based on placebo-controlled trials, which demonstrate significant improvements in itch scores. However, there is no direct comparison to active standard-of-care treatments, limiting the ability to assess relative efficacy. The phase 3 trial shows a statistically significant reduction in itch compared to placebo, but the absence of head-to-head data against active treatments results in a B++ rating.
Does the economic case hold at the expected price? — Cost effectiveness
There is no available data on cost-effectiveness, including ICERs or QALYs, which are critical for assessing economic value. The NICE appraisal is still awaiting development, indicating that cost-effectiveness evidence is not yet available, leading to a C rating.
Is there quality-of-life evidence payers weigh? — Quality of life
While the treatment shows improvements in itch and sleep interference, there are no utility values or comprehensive HRQoL data available. The use of validated instruments is noted, but the absence of generic health utility measures limits the ability to derive QALYs, resulting in a B+ rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile shows a high incidence of diarrhea, but overall, the treatment is considered safe with manageable adverse effects. The phase 2 and phase 3 trials report no serious adverse events, and the adverse effects are well characterized, justifying an A+ rating.
Was the drug compared against what payers expect? — Comparator Selection
The pivotal trial uses placebo as a comparator, which is appropriate for establishing efficacy but does not reflect real-world treatment practices. The absence of active comparators limits the relevance of the findings for HTA purposes, resulting in a B+ rating.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is largely representative of the intended patient population with primary biliary cholangitis. However, subgroup analyses are limited, which affects the generalizability of the findings slightly, leading to an A rating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment can be integrated into existing care pathways with minimal disruption. The oral administration route and straightforward diagnostic requirements support its integration, justifying an A+ rating.
Are the wider system costs understood? — Resource Use and Cost Implications
While there are implications for resource use due to monitoring requirements, no specific cost data are available. The potential for increased healthcare utilization due to monitoring and management of adverse effects leads to a B rating.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on multiple randomized controlled trials, providing a strong internal validity. However, the reliance on post hoc analyses in phase 2b raises some concerns about robustness, leading to an A rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is moderate uncertainty regarding the long-term effects and broader impacts of the treatment. While clinical outcomes are statistically supported, the absence of economic sensitivity analyses and broader system impact data leads to a B+ rating.
